Leeds Ira L, Alturki Hasan, Canner Joseph K, Schneider Eric B, Efron Jonathan E, Wick Elizabeth C, Gearhart Susan L, Safar Bashar, Fang Sandy H
Department of Surgery, The Johns Hopkins Hospital, 600 North Wolfe Street, Blalock 618, Baltimore, MD, 21287, USA.
Johns Hopkins Surgery Center for Outcomes Research, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, USA.
World J Surg Oncol. 2016 Aug 5;14(1):208. doi: 10.1186/s12957-016-0970-x.
The incidence of anal cancer in human immunodeficiency virus (HIV)-positive individuals is increasing, and how co-infection affects outcomes is not fully understood. This study sought to describe the current outcome disparities between anal cancer patients with and without HIV undergoing abdominoperineal resection (APR).
A retrospective review of all US patients diagnosed with anal squamous cell carcinoma, undergoing an APR, was performed. Cases were identified using a weighted derivative of the Healthcare Utilization Project's National Inpatient Sample (2000-2011). Patients greater than 60 years old were excluded after finding a skewed population distribution between those with and without HIV infection. Multivariable logistic regression and generalized linear modeling analysis examined factors associated with postoperative outcomes and cost. Perioperative complications, in-hospital mortality, length of hospital stay, and hospital costs were compared for those undergoing APR with and without HIV infection.
A total of 1725 patients diagnosed with anal squamous cell cancer undergoing APR were identified, of whom 308 (17.9 %) were HIV-positive. HIV-positive patients were younger than HIV-negative patients undergoing APR for anal cancer (median age 47 years old versus 51 years old, p < 0.001) and were more likely to be male (95.1 versus 30.6 %, p < 0.001). Postoperative hemorrhage was more frequent in the HIV-positive group (5.1 versus 1.5 %, p = 0.05). Mortality was low in both groups (0 % in HIV-positive versus 1.49 % in HIV-negative, p = 0.355), and length of stay (LOS) (10+ days; 75th percentile of patient data) was similar (36.9 % with HIV versus 29.8 % without HIV, p = 0.262). Greater hospitalization costs were associated with patients who experienced a complication. However, there was no difference in hospitalization costs seen between HIV-positive and HIV-negative patients (p = 0.66).
HIV status is not associated with worse postoperative recovery after APR for anal cancer as measured by length of stay or hospitalization cost. Further study may support APRs to be used more aggressively in HIV-positive patients with anal cancer.
人类免疫缺陷病毒(HIV)阳性个体中肛门癌的发病率正在上升,而合并感染如何影响治疗结果尚未完全明确。本研究旨在描述接受腹会阴联合切除术(APR)的HIV阳性和阴性肛门癌患者目前的治疗结果差异。
对所有诊断为肛门鳞状细胞癌并接受APR的美国患者进行回顾性研究。使用医疗保健利用项目国家住院样本(2000 - 2011年)的加权衍生数据识别病例。在发现HIV感染患者与未感染患者之间的人群分布存在偏差后,排除了年龄大于60岁的患者。多变量逻辑回归和广义线性模型分析检查了与术后结果和费用相关的因素。比较了接受APR的HIV感染患者和未感染患者的围手术期并发症、住院死亡率、住院时间和住院费用。
共识别出1725例诊断为肛门鳞状细胞癌并接受APR的患者,其中308例(17.9%)为HIV阳性。接受APR治疗肛门癌的HIV阳性患者比HIV阴性患者年轻(中位年龄47岁对51岁,p < 0.001),且更可能为男性(95.1%对30.6%,p < 0.001)。HIV阳性组术后出血更频繁(5.1%对1.5%,p = 0.05)。两组死亡率均较低(HIV阳性组为0%,HIV阴性组为1.49%,p = 0.355),住院时间(LOS)(10天以上;患者数据的第75百分位数)相似(HIV阳性组为36.9%,HIV阴性组为29.8%,p = 0.262)。发生并发症的患者住院费用更高。然而,HIV阳性和阴性患者的住院费用没有差异(p = 0.66)。
以住院时间或住院费用衡量,HIV状态与肛门癌APR术后恢复较差无关。进一步的研究可能支持在HIV阳性肛门癌患者中更积极地使用APR。